Why the study?
To review the evidence regarding the pharmacological inhibition of ApoCIII as a potential target to lower triglyceride-rich lipoproteins and cardiovascular risk in patients with hypertriglyceridemia.
Does pharmacological inhibition of ApoCIII reduce plasma levels of triglyceride-rich lipoproteins in patients with hypertriglyceridemia?
Does pharmacological inhibition of ApoCIII reduce plasma levels of triglyceride-rich lipoproteins in patients with hypertriglyceridemia?
This review summarizes the molecular function of ApoCIII and the lipid-lowering potential of its pharmacological inhibition, particularly with Volanesorsen, in patients with hypertriglyceridemia.
May lower pancreatitis risk in severe HTG; leaves open ASCVD benefit from ApoCIII inhibition.
PURPOSE OF REVIEW: This review will briefly revise the evidence concerning the pharmacological inhibition of Apolipoprotein CIII (ApoCIII) in patients with hypertriglyceridemia. RECENT FINDINGS: ApoCIII is a plasma apolipoprotein playing a major role in the metabolism of triglyceride-rich lipoproteins, namely chylomicrons and very-low-density lipoproteins as well as in the pathological processes involved in atherosclerosis. Therefore, ApoCIII is a potential new target for reducing plasma levels of TRLs and, thereby, cardiovascular risk. In recent years, there have been extensive preclinical and clinical pharmacological studies aimed at testing drugs directed against ApoCIII. SUMMARY: In this review, firstly we will summarize the molecular function of ApoCIII in lipoprotein metabolism. Then, we will examine the lipid-lowering potential of the pharmacological inhibition of ApoCIII based on the results of clinical trial employing Volansesorsen, the first approved antisense therapeutic oligonucleotide against ApoCIII mRNA. The future perspectives for ApoCIII inhibition will be also revised.
No takes yet. Share an insight, caveat, or question.
Tramontano et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: